Interleukin-1β-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors

Cancer Research

Volumn 67, Issue 3, 2007, Pages 1062-1071

  Krelin, Yakov ^a   Voronov, Elena ^a   Dotan, Shahar ^a   Elkabets, Moshe ^a   Reich, Eli ^e   Fogel, Mina ^b   Huszar, Monika ^b   Iwakura, Yoichiro ^c   Segal, Shraga ^a   Dinarello, Charles A ^d   Apte, Ron N ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF COLORADO   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CARCINOGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; OLIVE OIL; TUMOR NECROSIS FACTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FIBROSARCOMA; FOREIGN BODY GRANULOMA; INFLAMMATION; LEUKOCYTE; MACROPHAGE; MICROENVIRONMENT; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; COCARCINOGENESIS; GENETICS; IMMUNOLOGY; MOUSE MUTANT; PATHOLOGY;

ANIMALS; CARCINOGENS; COCARCINOGENESIS; FEMALE; FIBROSARCOMA; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; LEUKOCYTES; METHYLCHOLANTHRENE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASM INVASIVENESS;

EID: 33847060965     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2956     Document Type: Article

References (50)

1. Nathan C. Points of control in inflammation. Nature 2002;420:846-52.
2. Clevers H. At the crossroads of inflammation and cancer. Cell 2004;118:671-4.
3. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-7.
4. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med 2001;193:F23-6.
5. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006;124:823-35.
6. Nickoloff BJ, Ben-Neriah Y, Pikarsky E. Inflammation and cancer: is the link as simple as we think? J Invest Dermatol 2005;124:x-xiv.
7. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004;14:433-9.
8. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.
9. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004;4:641-8.
10. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
11. Apte RN, Voronov E. Interleukin-1 - a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 2002;12:277-90.
12. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005;201:1355-59.
13. Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 2004;4:378-85.
14. Mantovani A, Locati M, Polentarutti N, Vecchi A, Garlanda C. Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll-like receptors: the new entry TIR8/SIGIRR. J Leukoc Biol 2004;75:738-42.
15. O'Neill LA. Signal transduction pathways activated by the IL-1 receptor/toll-like receptor superfamily. Curr Top Microbiol Immunol 2002;270:47-61.
16. Martin MU, Wesche H. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochim Biophys Acta 2002;1592:265-80.
17. Werman A, Werman-Venkert R, White R, et al. The precursor form of IL-1α is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA 2004;101:2434-9.
18. Douvdevani A, Huleihel M, Zoller M, Segal S, Apte RN. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1α either spontaneously or following IL-1α gene transfer. Int J Cancer 1992;51:822-30.
19. Dvorkin T, Song X, Argov S, et al. Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1{α}. J Leukoc Biol 2006;80:96-106.
20. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 2003;100:2645-50.
21. Zoller M, Douvdevani A, Segal S, Apte RN. Interleukin-1 produced by tumorigenic fibroblasts influences tumor rejection. Int J Cancer 1992;50:443-9.
22. Zoller M, Douvdevani A, Segal S, Apte RN. Interleukin-1 production by transformed fibroblasts. II. Influence on antigen presentation and T-cell-mediated antitumor response. Int J Cancer 1992;50:450-7.
23. Song X, Voronov E, Dvorkin T, et al. Differential effects of IL-1α and IL-1β on tumorigenicity patterns and invasiveness. J Immunol 2003;171:6448-56.
24. Song X Krelin Y, Dvorkin T, et al. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1{β}-secreting cells. J Immunol 2005;175:8200-8.
25. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006;176:284-90.
26. Saijo Y, Tanaka M, Miki M, et al. Proinflammatory cytokine IL-1β promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol 2002;169:469-75.
27. Weinreich DM, Elaraj DM, Puhlmann M, et al. Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice. Cancer Res 2003;63:5957-61.
28. Elaraj DM, Weinreich DM, Varghese S, et al. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res 2006;12:1088-96.
29. Arnott CH, Scott KA, Moore RJ, et al. Tumour necrosis factor-α mediates tumour promotion via a PKCα- and AP-1-dependent pathway. Oncogene 2002;21:4728-38.
30. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002;13:135-41.
31. Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H. Essential role of tumor necrosis factor α (TNF-α) in tumor promotion as revealed by TNF-α-deficient mice. Cancer Res 1999;59:4516-8.
32. Szlosarek PW, Balkwill FR. Tumour necrosis factor α: a potential target for the therapy of solid tumours. Lancet Oncol 2003;4:565-73.
33. Knight B, Yeoh GC, Husk KL, et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 2000;192:1809-18.
34. Greten FR, Eckmann L, Greten TF, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
35. Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-6.
36. Horai R, Asano M, Sudo K, et al. Production of mice deficient in genes for interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1α is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 1998;187:1463-75.
37. Slaga TJ, Gleason GL, Hardin L. Comparison of the skin tumor initiating activity of 3-methylcholanthrene and 3,11-dimethylcholanthrene in mice. Cancer Lett 1979;7:97-102.
38. Vazquez-Torres A, Fantuzzi G, Edwards CK III, Dinarello CA, Fang FC. Defective localization of the NADPH phagocyte oxidase to Salmonella-containing phagosomes in tumor necrosis factor p55 receptor-deficient macrophages. Proc Natl Acad Sci U S A 2001;98:2561-5.
39. Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20.
40. Horai R, Nakajima A, Habiro K, et al. TNF-α is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J Clin Invest 2004;114:1603-11.
41. Hata H, Sakaguchi N, Yoshitomi H, et al. Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 2004;114:582-8.
42. Iwakura Y. Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev 2002;13:341-55.
43. Sims JE. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 2002;14:117-22.
44. Weitzman SA, Weitberg AB, Clark EP, Stossel TP. Phagocytes as carcinogens: malignant transformation produced by human neutrophils. Science 1985;227:1231-3.
45. Miller LS, O'Connell RM, Gutierrez MA, et al. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity 2006;24:79-91.
46. Amit S, Ben-Neriah Y. NF-κB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol 2003;13:15-28.
47. Blankenstein T, Qin Z. Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance. Adv Cancer Res 2003;90:179-207.
48. Qin Z, Kim HJ, Hemme J, Blankenstein T. Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction. J Exp Med 2002;195:1479-90.
49. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7:411-23.
50. Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D. Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 2003;197:1017-28.